New blood thinner trial aims to prevent rebleeding in liver patients
NCT ID NCT07602062
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether the blood thinner rivaroxaban can safely improve outcomes in people with liver cirrhosis who have both a blood clot in the portal vein and a high risk of variceal bleeding. About 175 participants will receive rivaroxaban or standard care starting 48 hours after endoscopic treatment. The goal is to see if it reduces rebleeding, clot worsening, and other serious complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Rivaroxaban (a blood thinner)
What this could lead to
If it works, this could offer a safer way to manage blood clots in cirrhosis patients and reduce the risk of rebleeding and other complications.
What could go wrong
This is an early-stage trial with only 175 participants, so results may not apply to everyone. The main risk is bleeding, which could be serious in these patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CIRRHOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dr. Huang xiaoquan
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••